Skip to content
Open in App
Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

web2

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in th...

Symbol · J7Z
Company profile

About

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

People

Company team

TW

Ted W. Love

Independent Director

Company leadership profile.

RD

Renee D. Gala

President, CEO & Director

Company leadership profile.

HA

Heather Ann McSharry

Independent Director

Company leadership profile.

BC

Bruce C. Cozadd

Co-Founder & Chairman

Company leadership profile.

JE

Jennifer E. Cook

Independent Non-Executive Director

Company leadership profile.

PT

Patrick T. Kennedy

Independent Director

Company leadership profile.

RE

Rick E. Winningham

Lead Independent Director

Company leadership profile.

PG

Patrick Gerald Enright

Independent Director

Company leadership profile.

SC

Seamus C. Mulligan

Independent Director

Company leadership profile.

NG

Norbert G. Riedel

Independent Director

Company leadership profile.

AO

Anne O'Riordan

Independent Director

Company leadership profile.

MD

Mark Douglas Smith

Independent Non-Executive Director

Company leadership profile.

LJ

Laura Jean Hamill

Independent Director

Company leadership profile.

Expert coverage

1 expert evaluated Jazz Pharmaceuticals.

Orbitrum research

Experts evaluating Jazz Pharmaceuticals

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment